Ian Wilmut has applied to HFEA for a permit to investigate potential cell therapeutics for ALS, using human embryonic cells produced through cloning. The news announcements, even this one come from a short news conference so little is really known. Wilmut’s presence in this area at this time could scarcely be more volatile for the US election-year debate about “who will get ahead” in hES research under US restrictions.
Labels: ALS, clinical research, hESC, HFEA, Ian Wilmut, stem cell research, stem cell therapy